Exilby: Europe Approves First Cannabis-Based Drug to Combat Chronic Pain and Displace Opioids

Unlike isolated synthetic cannabinoids, Exilby is a standardized full-spectrum extract taken as an oral liquid tincture (drops). It is derived from Vertanical’s patented Cannabis sativa DKJ127 L. genetics, which were specifically selected for pain management from over 500 strains based on their unique phytochemical profile . The formulation contains a full range of cannabinoid compounds, including low levels of THC, to manage pain while aiming to minimize psychoactive effects .

Clinical Proof: How Does Exilby Compare to Existing Drugs?

The authorization is heavily supported by two pivotal Phase 3 trials, with results published in peer-reviewed journals like Nature Medicine . The data addresses two urgent questions for clinicians: whether the drug works long-term, and how it stacks up against the current standard of care.

Sustained Pain Relief: In a large placebo-controlled trial, patients on Exilby experienced a 1.9-point mean pain reduction on an 11-point numerical rating scale (NRS). Crucially, this effect was not fleeting; it was sustained over a 12-month period, a significant metric for a chronic condition. The trials involved over 1,200 patients, with findings indicating the drug was generally well tolerated .

Head-to-Head ELEVATE Trial: In a direct comparison designed to test its opioid-sparing potential, Exilby was benchmarked against opioid analgesics. The results showed superior pain relief alongside better gastrointestinal tolerability. Critically, across the entire clinical program, investigators observed no evidence of dependence, withdrawal symptoms, or abuse potential, the primary dangers associated with long-term opioid use .

A Global Regulatory Push

With Europe secured, Vertanical is moving aggressively to gain worldwide authorization for what it views as a first-in-class non-opioid therapy.

United States: The U.S. Food and Drug Administration (FDA) granted VER-01 Breakthrough Therapy Designation on May 18, 2026. This is the first such designation ever for a cannabis-based pain medication, and only the second FDA recognition for any cannabis-derived drug since Epidiolex in 2018 . This status is reserved for therapies that demonstrate substantial improvement over existing options for serious conditions. An additional U.S. Phase 3 trial is currently underway, with the company planning to submit a New Drug Application (NDA) in 2028 .

United Kingdom and EU: Vertanical has announced plans to submit for marketing authorization in the UK by the end of 2026, with approval expected shortly afterward . The company also intends to leverage the European mutual recognition procedure to expand access across the broader European Union following the initial German and Austrian approvals .

Market Availability and Pricing

Patients will not have to wait long to access the therapy. Vertanical has guided that Exilby will be available to consumers in Germany and Austria in autumn 2026 . The drug is expected to be eligible for reimbursement according to the national statutory health insurance processes in those countries .

The Vision: Replacing Opioids

The man behind Vertanical, billionaire entrepreneur and founder Clemens Fischer, has framed Exilby as a direct challenger to the opioid market. He has stated that the drug “could replace opiates” because it provides effective analgesia without the dependency spiral that has driven a global public health crisis . The timing is significant; the German-language press reports that this approval represents the first new drug class in pain therapy in around 15 years .